GlassScriptPhysician profile
John M Woytowicz
NPI 1205802212
$2,923.16
in general payments reported to CMS, 2019-2025
22 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $219 · 2021: $77.78 · 2022: $122 · 2023: $438 · 2024: $1,596 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $535.94 | 2020-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $396.21 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $315.08 | 2023-2025 | Vraylar |
| Exact Sciences Corporation | $233.87 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $211.00 | 2023-2025 | |
| Novo Nordisk INC | $176.81 | 2020-2025 | Rybelsus, Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $164.66 | 2023-2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $162.90 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $119.02 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $99.48 | 2020-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.04 | 2020-2024 | Jardiance |
| Astellas Pharma US INC | $88.22 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $68.60 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $60.28 | 2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.05 | 2024-2025 | Xifaxan, Trulance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.89 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $28.85 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $18.55 | 2022 | |
| Circassia INC. | $17.49 | 2020 | |
| Sumitomo Pharma America, INC. | $16.48 | 2024 | Gemtesa |
| Alkermes, INC. | $15.22 | 2025 | Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Woytowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.